Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck

Schöffski, Patrick; Catimel, G.; Planting, A. S. T.; Jp, Droz; Verweij, Jaap; Schrijvers, Dirk; Gras, L.; Schrijvers, Ad H. G. J.; Wanders, J.; Hanauske, A.-R.

doi:10.1023/a:1008360323986

Cited by 94 publications

(54 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Docetaxel -cisplatin appeared to be a more effective combination, with overall response rates ranging from 33 to 76% (Kienzer et al, 1998;Schoffski et al, 1999;Specht et al, 2000;Glisson et al, 2002). In the trial conducted by the European Organisation for the Research and Treatment of Cancer (EORTC), docetaxel (100 mg m À2 ) plus cisplatin (75 mg m À2 ) produced a response rate of 54% (Schoffski et al, 1999). Of the 44 patients enrolled in this trial, 22 were chemotherapy-naïve and the response rate in this group was 86%.…”

Section: Potential Of Docetaxel In Scchnmentioning

confidence: 99%

“…Of the 44 patients enrolled in this trial, 22 were chemotherapy-naïve and the response rate in this group was 86%. As with single-agent docetaxel, the main toxicity in each of the combination studies was myelosuppression (Kienzer et al, 1998;Schoffski et al, 1999;Colevas et al, 2000;Specht et al, 2000;Tubiana-Mathieu et al, 2000;Glisson et al, 2002). Mucositis was more commonly seen in the combination studies (particularly docetaxel -5-FU) than with single-agent docetaxel.…”

Section: Potential Of Docetaxel In Scchnmentioning

confidence: 99%

See 1 more Smart Citation

Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck

Posner

Lefèbvre

2003

Br J Cancer

View full text Add to dashboard Cite

Patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) are often treated with induction chemotherapy or chemoradiotherapy, but to date without major impact on survival. The combination of cisplatin -5-fluorouracil (5-FU) (PF) has been used as standard induction therapy; however, poor patient survival has stimulated investigation into new agents with potential activity in SCCHN. Docetaxel has significant single-agent activity in SCCHN and has been investigated in combination with PF regimens as induction therapy. The results of six phase II studies of docetaxel -PF regimens (TPF) as induction in locally advanced SCCHN patients are reviewed and reported. Consistently, high 2-year survival rates and overall response rates were demonstrated across the phase II trials in the range 42 -82 and 71 -100%, respectively. The toxicity profile seen with TPF-based regimens was acceptable. The primary toxicity was neutropenia, which together with gastrointestinal complaints accounted for the majority of adverse events. Given the encouraging phase II experience with TPF-based regimens, two large-scale phase III studies comparing TPF-based regimens with standard PF regimens are underway. The results have significant potential for validating the findings of the phase II studies, demonstrating improved survival and overall response of patients treated with docetaxel-based induction chemotherapy.

show abstract

Section: Potential Of Docetaxel In Scchnmentioning

confidence: 99%

Section: Potential Of Docetaxel In Scchnmentioning

confidence: 99%

Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck

Posner

Lefèbvre

2003

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…As an inhibitor of microtubule depolymerization, docetaxel is approximately twice as potent as paclitaxel, prompting many investigators to study its cytotoxicity in a variety of cell lines [25]. Further clinical studies have shown docetaxel to have potent anti-tumor activity against several human tumors, including ovarian [20], anthracycline-resistant breast [4,30], non-small cell lung [6,10,12] and head and neck squamous cell cancer [7,31]. However, its systemic use against CNS tumors has demonstrated no significant improvement in survival [9,29].…”

Section: Discussionmentioning

confidence: 99%

“…Its mechanism of action is through inhibition of tubulin depolymerization resulting in microtubule aggregation and cell death [33]. Docetaxel has shown efficacy in clinical trials against a variety of human tumors [4,6,7,10,12,20,30,31], as well as having been reported to act as a potent radiosensitizer against systemic malignancies [19,21,23,24]. In two Phase II trials, docetaxel showed no significant efficacy when given intravenously to patients with malignant glioma [9,29].…”

Section: Introductionmentioning

confidence: 99%

Interstitial Docetaxel (Taxotere), Carmustine and Combined Interstitial Therapy: a Novel Treatment for Experimental Malignant Glioma

et al. 2006

View full text Add to dashboard Cite

Docetaxel (Taxotere ® ) is a hemisynthetic, anti-cancer compound with good preclinical and clinical activity in a variety of systemic neoplasms. We tested its activity against malignant gliomas using local delivery methods. Antitumor activity was assessed in vitro against human and rat brain-tumor cell lines. For in vivo evaluation, we incorporated docetaxel into a biodegradable polymer matrix, determined associated toxicity in the rat brain, and measured efficacy at extending survival in a rat model of malignant glioma. Also, we examined the combined local delivery of docetaxel with carmustine (BCNU) against the experimental intracranial glioma. Rats bearing intracranial 9L gliosarcomas were treated 5 days after tumor implantation with various polymers (placebo, 5% docetaxel, 3.8% BCNU, or 5% docetaxel and 3.8% BCNU combination). Animals receiving docetaxel polymers (n = 15, median survival 39.1 days) had significantly improved survival over control animals (n = 12, median survival 22.5 days, P = 0.01). Similarly, animals receiving BCNU polymers (n = 15, median survival 39.3 days, 13.3% long-term survivors) demonstrated an increase in survival compared to the controls (P = 0.04). Animals receiving the combination polymers demonstrated a modest increase in survival compared to either chemotherapeutic agent alone (n = 14, median survival 54.9 days, 28.6% long-term survivors) with markedly improved survival over controls (P = 0.003). We conclude that locally delivered docetaxel shows promise as a novel antiglioma therapy and that the combination of drug regimens via biodegradable polymers may be a great therapeutic benefit to patients with malignant glioma.

show abstract

“…Grade 3 toxicities both hematologic and nonhematological were common. There were six complete responses (15%) and 16 partial responses (39%), resulting in an overall response rate of 54% in the intent-to-treat population [50].…”

Section: Docetaxel With Cisplatinmentioning

confidence: 99%

Role of Taxoids in Head and Neck Cancer

Schrijvers

Vermorken

2000

The Oncologist

Self Cite

View full text Add to dashboard Cite

Docetaxel and paclitaxel represent a new class of cytotoxic agents having both a specific chemical structure and mechanism of action. They act to promote tubulin polymerization and the formation of stable microtubules. The microtubules produced in the presence of taxoids are resistant to disassembly by physiologic stimuli, and cells exposed to these agents exhibit an accumulation of disorganized microtubule arrays. This affects the normal mitotic process and eventually results in cell death.Both drugs are active as single agents in patients with head and neck cancer with response rates ranging from 20% to 40%. They may be combined with other cytotoxic agents, radiotherapy, or both. A review is given of the presently available data.

show abstract

Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck

Abstract: The combination of docetaxel and cisplatin is feasible and active in locally advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck.

Cited by 94 publications

References 9 publications

Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck

Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck

Interstitial Docetaxel (Taxotere), Carmustine and Combined Interstitial Therapy: a Novel Treatment for Experimental Malignant Glioma

Role of Taxoids in Head and Neck Cancer

Contact Info

Product

Resources

About